Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, September 27.
9 Things To Watch In The Week Ahead. Stocks mentioned: Paychex (PAYX), Walgreen (WAG), Monsanto (MON), Clorox (CLX), Eli Lilly (LLY). Other stocks mentioned: Hain Celestial (HAIN), Diamond Resorts (DRII)
Cramer would look at the events in the week ahead with an eye on Washington and the gridlock that could ensue.
Manufacturing numbers from China should be positive.
Paychex (PAYX) is up over 40%. It might give up its gain because of Washington, but Cramer thinks it may be a buy.
Manufacturing data from North America may be robust, but good news might not be able to resist pressure from Washington D.C.
Walgreen (WAG) is spreading its wings and taking back market share while it expands internationally. Cramer would buy if it pulls back.
Ben Bernanke speaks: Whatever he says may move the markets, so beware.
Monsanto (MON) has been roaring. It may be a buy on a decline.
Clorox (CLX) reports and may give good news about its restructuring program.
Eli Lilly (LLY) reported bad news about a new cancer drug. Management might say something good.
Employment Number: Cramer expects it to be positive.
Cramer took some calls:
Hain Celestial (HAIN): The long-term trend for healthy eating is strong. Cramer would stay with HAIN.
Diamond Resorts (DRII) came public when the market was soggy. Cramer thinks it is a good stock.
CEO Interview: Ron Squarer, Array BioPharma (ARRY)
Array BioPharma (ARRY) has six phase 3 trial cancer drugs and has partnerships with major players in the pharma space. The stock is up 64% for the year and 23% since Cramer recommended it in July. CEO Ron Squarer discussed the company's revolutionary treatments, its lucrative partnerships and its strong pipeline. Cramer told investors to do research on the company's great potential.
Pharmacyclics (PCYC) may have one of the biggest anti-cancer drugs of all-time. The company has an anti-cancer drug that may have multiple applications and could be worth $9 billion. Its use on lymphoma patients has produced a 68% positive response rate and it has already had huge peak sales. The drug could also be used on other blood cancers, which means that PCYC could double in value. In case PCYC doesn't live up to the hype, Cramer would consider it a speculative play and use market orders when buying. "Pharmacyclics is the real thing," said Cramer.
Cramer took a call:
Boston Scientific (BSX): "This is an earnings turnaround story," Cramer said. BSX has been on the floor so long, it has been hard to recommend, but he would buy it now.
Jim Cramer's Action Alerts PLUS: Trade right alongside a Wall Street pro! Start your 14-day FREE trial today.
Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.